Synovus Financial’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $76.8M | Sell |
100,668
-1,390
| -1% | -$1.03M | 0.88% | 20 |
|
|
2025
Q2 | $79.6M | Sell |
102,058
-3,278
| -3% | -$2.55M | 0.97% | 19 |
|
|
2025
Q1 | $87M | Sell |
105,336
-1,884
| -2% | -$1.57M | 1.13% | 17 |
|
|
2024
Q4 | $82.8M | Sell |
107,220
-2,773
| -3% | -$2.3M | 1.05% | 17 |
|
|
2024
Q3 | $97.5M | Sell |
109,993
-6,041
| -5% | -$5.43M | 1.13% | 14 |
|
|
2024
Q2 | $105M | Sell |
116,034
-878
| -0.8% | -$702K | 1.39% | 14 |
|
|
2024
Q1 | $91M | Sell |
116,912
-478
| -0.4% | -$340K | 1.18% | 14 |
|
|
2023
Q4 | $68.4M | Sell |
117,390
-29,179
| -20% | -$17M | 0.97% | 16 |
|
|
2023
Q3 | $78.7M | Sell |
146,569
-5,013
| -3% | -$2.58M | 0.9% | 18 |
|
|
2023
Q2 | $71.1M | Sell |
151,582
-2,481
| -2% | -$1.04M | 0.78% | 21 |
|
|
2023
Q1 | $52.9M | Sell |
154,063
-3,663
| -2% | -$1.24M | 0.6% | 29 |
|
|
2022
Q4 | $57.7M | Sell |
157,726
-912
| -0.6% | -$323K | 0.66% | 26 |
|
|
2022
Q3 | $51.3M | Sell |
158,638
-2,604
| -2% | -$825K | 0.63% | 26 |
|
|
2022
Q2 | $52.2M | Buy |
161,242
+4,260
| +3% | +$1.28M | 0.61% | 29 |
|
|
2022
Q1 | $45M | Sell |
156,982
-8,017
| -5% | -$2.06M | 0.48% | 29 |
|
|
2021
Q4 | $45.6M | Buy |
164,999
+2,305
| +1% | +$584K | 0.45% | 31 |
|
|
2021
Q3 | $37.6M | Sell |
162,694
-2,793
| -2% | -$689K | 0.4% | 35 |
|
|
2021
Q2 | $38M | Sell |
165,487
-356
| -0.2% | -$71.5K | 0.38% | 36 |
|
|
2021
Q1 | $31M | Buy |
165,843
+544
| +0.3% | +$106K | 0.35% | 41 |
|
|
2020
Q4 | $27.9M | Buy |
165,299
+1,245
| +0.8% | +$186K | 0.32% | 42 |
|
|
2020
Q3 | $24.3M | Sell |
164,054
-10,164
| -6% | -$1.57M | 0.32% | 47 |
|
|
2020
Q2 | $28.6M | Sell |
174,218
-21,795
| -11% | -$3.35M | 0.41% | 38 |
|
|
2020
Q1 | $27.2M | Buy |
196,013
+23,783
| +14% | +$3.27M | 0.38% | 45 |
|
|
2019
Q4 | $22.6M | Buy |
172,230
+30
| +0% | +$3.48K | 0.31% | 51 |
|
|
2019
Q3 | $19.3M | Buy |
172,200
+2,473
| +1% | +$275K | 0.29% | 54 |
|
|
2019
Q2 | $18.8M | Buy |
169,727
+295
| +0.2% | +$34.7K | 0.28% | 56 |
|
|
2019
Q1 | $22M | Sell |
169,432
-1,421
| -0.8% | -$173K | 0.36% | 48 |
|
|
2018
Q4 | $19.8M | Sell |
170,853
-24,349
| -12% | -$2.72M | 0.36% | 51 |
|
|
2018
Q3 | $20.9M | Sell |
195,202
-3,824
| -2% | -$382K | 0.33% | 48 |
|
|
2018
Q2 | $17M | Sell |
199,026
-1,277
| -0.6% | -$105K | 0.28% | 54 |
|
|
2018
Q1 | $15.5M | Buy |
200,303
+570
| +0.3% | +$45.9K | 0.26% | 61 |
|
|
2017
Q4 | $16.8M | Buy |
199,733
+3,091
| +2% | +$263K | 0.29% | 55 |
|
|
2017
Q3 | $16.8M | Buy |
196,642
+1,537
| +0.8% | +$126K | 0.32% | 51 |
|
|
2017
Q2 | $16M | Sell |
195,105
-19,557
| -9% | -$1.6M | 0.32% | 51 |
|
|
2017
Q1 | $18M | Buy |
214,662
+1,123
| +0.5% | +$89.9K | 0.38% | 46 |
|
|
2016
Q4 | $15.7M | Buy |
213,539
+4,188
| +2% | +$312K | 0.36% | 47 |
|
|
2016
Q3 | $16.8M | Buy |
209,351
+6,018
| +3% | +$482K | 0.39% | 44 |
|
|
2016
Q2 | $16.1M | Buy |
203,333
+8,406
| +4% | +$633K | 0.37% | 45 |
|
|
2016
Q1 | $14M | Buy |
194,927
+7,132
| +4% | +$540K | 0.34% | 47 |
|
|
2015
Q4 | $15.8M | Buy |
187,795
+4,581
| +3% | +$380K | 0.39% | 49 |
|
|
2015
Q3 | $15.3M | Buy |
183,214
+28,553
| +18% | +$2.41M | 0.41% | 41 |
|
|
2015
Q2 | $12.9M | Buy |
154,661
+318
| +0.2% | +$24.2K | 0.33% | 53 |
|
|
2015
Q1 | $11.2M | Buy |
154,343
+862
| +0.6% | +$61.4K | 0.29% | 61 |
|
|
2014
Q4 | $10.6M | Buy |
153,481
+287
| +0.2% | +$19.4K | 0.28% | 62 |
|
|
2014
Q3 | $9.91M | Sell |
153,194
-11,667
| -7% | -$739K | 0.28% | 63 |
|
|
2014
Q2 | $10.2M | Buy |
164,861
+94
| +0.1% | +$5.61K | 0.29% | 57 |
|
|
2014
Q1 | $9.71M | Sell |
164,767
-402
| -0.2% | -$22.4K | 0.29% | 58 |
|
|
2013
Q4 | $8.43M | Sell |
165,169
-24,871
| -13% | -$1.25M | 0.24% | 63 |
|
|
2013
Q3 | $9.59M | Sell |
190,040
-79,869
| -30% | -$4.18M | 0.3% | 54 |
|
|
2013
Q2 | $13.3M | Buy |
+269,909
| New | +$14.7M | 0.41% | 42 |
|
Other funds holding LLY
Synovus Financial's LLY Position: Q3 2025 in Review
Synovus Financial reduced its Eli Lilly (LLY) stake by 1.4% in Q3 2025, selling an estimated $1.03M and leaving 100,668 shares worth $76.8M. The position accounts for 0.88% of the portfolio, ranked #20.
Synovus Financial first reported a position in LLY in Q2 2013 and has held it in 50 quarters since. The position peaked at $105M in Q2 2024. 3,897 funds tracked by Wall St. Rank hold LLY as of Q3 2025.
- Synovus Financial held 100,668 shares of Eli Lilly worth $76.8M as of Q3 2025.
- Synovus Financial sold 1,390 Eli Lilly shares in Q3 2025, an estimated $1.03M.
- Eli Lilly made up 0.88% of Synovus Financial's portfolio in Q3 2025, its #20 holding.
- Synovus Financial first reported a position in Eli Lilly in Q2 2013 and has held it in 50 quarters since.
- Synovus Financial's Eli Lilly position peaked at $105M in Q2 2024.
- 3,897 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2025.
Based on Synovus Financial's 13F filing for Q3 2025, filed 7 Nov 2025.